SGLT2 Inhibitor for Severe Tricuspid Regurgitation

Sponsor
Samsung Medical Center
Study ID
NCT05686616
Status
Unknown

Conditions

  • Tricuspid Regurgitation

Eligibility Criteria

Sex
ALL
Age
20 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study to identify the efficacy of sodium glucose cotransporter 2 inhibitors add-on treatment on right ventricular remodeling and the amount of severe tricuspid regurgitation (TR) in patients with isolated severe TR.

Key Dates

Start date
Apr 13, 2022
Status verified
Jan 2023
Primary completion
Apr 13, 2024
Completion
Mar 3, 2025

Study Design

Enrollment
72 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: SGLT2 inhibitor group
    Participants will take dapagliflozin propanediol hydrate 12.3 mg once a day for a total of 48 weeks.
  • No Intervention: Conventional treatment group
    Participants will continue the existing medications for severe TR.

Primary Outcome Measure

Difference of RVESVi by CMR from baseline to 12 months follow-up (∆RVESVi) [ Time Frame: Baseline and month 12 ]

Central Contacts

Related Studies